DNA SEQUENCING AND EPIGENOME ANALYSIS
    145.
    发明公开
    DNA SEQUENCING AND EPIGENOME ANALYSIS 有权
    DNA-SEQUENZIERUNG UND EPIGENOMANALYSE

    公开(公告)号:EP3027775A4

    公开(公告)日:2017-04-12

    申请号:EP14832389

    申请日:2014-08-01

    Applicant: STC UNM

    Abstract: This disclosure describes, in one aspect, methods for DNA sequencing and performing epigenomic analyses. Generally, the methods include immobilizing a plurality of copies of a DNA molecule on a surface, stretching at least a portion of the immobilized DNA molecules, and sequencing at least a portion of the immobilized, stretched DNA molecules.

    Abstract translation: 在一个方面,本公开描述了用于DNA测序和进行表观基因组分析的方法。 通常,这些方法包括将多个DNA分子拷贝固定在表面上,拉伸至少一部分固定的DNA分子,并对至少一部分固定的,拉伸的DNA分子进行测序。

    IMMUNOGENIC HPV L2-CONTAINING VLPS AND RELATED COMPOSITIONS AND METHODS
    147.
    发明公开
    IMMUNOGENIC HPV L2-CONTAINING VLPS AND RELATED COMPOSITIONS AND METHODS 有权
    免疫缺陷型HPV L2-HALTIGE VLPS UND VERWANDTE ZUSAMMENSETZUNGEN UND VERFAHREN

    公开(公告)号:EP2802349A4

    公开(公告)日:2015-08-26

    申请号:EP13736349

    申请日:2013-01-10

    Applicant: STC UNM

    Abstract: In one aspect, the invention provides immunogenic HPV L2-containing viral-like particles (VLPs). Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. In certain aspects, the VLPs are comprised of a coat polypeptide of the bacteriophages PP7 or MS2, wherein the coat protein is modified by insertion of peptide antigens derived from HPV L2, and wherein the HPV L2 peptide is displayed on the VLP and encapsidates PP7 or MS2 mRNA. Specifically, VLPs of the invention display L2 peptides at the N- terminus of the bacteriophage coat protein. Surprisingly, these L2-displaying VLPs induce more broadly neutralizing antibody responses than when the same peptide is displayed in the AB-loop such that the immunogenic response is enhanced by a factor of at least 10. Immunogenic VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo.

    Abstract translation: 一方面,本发明提供了含免疫原性的含有HPV L2的病毒样颗粒(VLP)。 还提供了相关组合物(例如疫苗),核酸构建体和治疗方法。 在某些方面,VLP由噬菌体PP7或MS2的外壳多肽组成,其中通过插入衍生自HPV L2的肽抗原修饰外壳蛋白,并且其中HPV L2肽显示在VLP上并且包裹PP7或 MS2 mRNA。 具体地,本发明的VLP在噬菌体外壳蛋白的N-末端显示L2肽。 令人惊讶的是,这些L2显示的VLP诱导比在AB环中显示相同的肽更广泛的中和抗体应答,使得免疫原性应答增加至少10倍。本发明的免疫原性VLP和相关组合物诱导高 针对HPV L2的滴度抗体应答和在体内防止HPV挑战。

    FORMULATIONS CONTAINING LARGE-SIZE CARRIER PARTICLES FOR DRY POWDER INHALATION AEROSOLS
    149.
    发明公开
    FORMULATIONS CONTAINING LARGE-SIZE CARRIER PARTICLES FOR DRY POWDER INHALATION AEROSOLS 审中-公开
    制剂大载体AEROSOLE干粉吸入

    公开(公告)号:EP2328556A4

    公开(公告)日:2013-11-20

    申请号:EP09803599

    申请日:2009-07-30

    Applicant: STC UNM

    CPC classification number: A61K9/0075 Y10T428/2982

    Abstract: A dry powder inhaler may include a drug chamber configured to contain a formulation including carrier particles and working agent particles, a mouthpiece configured to direct flow of working agent particles to a user, and a retaining member proximal the mouthpiece. The retaining member be sized and arranged to prevent flow of substantially all carrier particles to the user while permitting flow of working agent particles to a user. The inhaler may include a formulation including carrier particles for delivering working agent to the pulmonary system of a patient. The carrier particles may have an average sieve diameter greater than about 500 μm. The carrier particles may be one of polystyrene, PTFE, silicone glass, and silica gel or glass.

Patent Agency Ranking